Abstract: The presently claimed invention provides for novel methods and kits for analyzing a collection of target sequences in a nucleic acid sample. A sample is amplified under conditions that enrich for a subset of fragments that includes a collection of target sequences. The invention further provides for analysis of the above sample by hybridization to an array, which may be specifically designed to interrogate the collection of target sequences for particular characteristics, such as, for example, the presence or absence of one or more polymorphisms.

Abstract: The present invention provides an agent for inhibiting metastasis of colorectal cancer and a method for inhibiting metastasis of colorectal cancer, which inhibit the function of Asef (i.e., binding activity to the APC gene product or guanine nucleotide exchange factor activity) that binds to the gene product of the tumor suppressor gene APC that plays an important role in tumorigenesis and in developmental processes, and/or inhibit the expression of the Asef gene.

Abstract: The present invention relates to compositions and methods for the preparation of modified nucleic acids. In particular, the present invention provides novel reagents and chemistries for the generation of linkers and modified phosphoramidates.

Abstract: The present invention provides isolated nucleic acid molecules encoding polypeptides comprising functional steroid hormone and juvenile hormone receptors, in particular isolated nucleic acid molecules which encode polypeptides comprising the Lucilia cuprina and Myzus persicae ecdysone receptors and juvenile hormone receptors. The present invention further provides functional recombinant steroid and juvenile hormone receptors and recombinant polypeptide subunits thereof and derivatives and analogues thereof. The present invention further provides screening systems and methods of identifying insecticidally-active agents which are capable of agonising or antagonising insect receptor function, or alternatively or in addition, which modify the affinity of said receptors for their cellular stimuli (eg. insect steroids or juvenile hormones) or analogues thereof, or alternatively or in addition, which act as insecticides by virtue of their ability to agonise or antagonise the activity of insect hormones.

Abstract: Nucleic acid compositions encoding novel chromo/fluoroproteins and mutants thereof, as well as the proteins encoded the same, are provided. The proteins of interest are proteins that are colored and/or fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that they are either obtained from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. Specific proteins of interest include the following specific proteins: hcriGFP; dendGFP; zoanRFP; scubGFP1; scubGFP2; rfloRFP; rfloGFP; mcavRFP; mcavGFP; cgigGFP; afraGFP; rfloGFP2; mcavGFP2; and mannFP. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.

Abstract: The hsp60 gene from a strain of Arthrobacter has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens.

Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

Abstract: Disclosed herein are nucleic acid molecules having sequences that are unique to Bacillus anthracis and method of making and using thereof. Also disclosed are kits comprising the nucleic acid molecules.

Abstract: The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.

Abstract: An improved process for preparing N6 -substituted aminopurine ribofuranose nucleosides. Compounds of this type are known to be usefull in the prepartation of compounds having activitity at adenosine receptors, e.g. Adenosine A1 receptor. The process comprises the step of reacting a 6-halopurine ribofuranose nucleoside with an amine in the presence of CaCO3 , wherein acid is added to the reaction mixture.

Abstract: The present invention refers to highly functionalised spiro-fused azetidinones of formula I: having a cyclohexane moiety with the desired number of protected or unprotected hydroxyl groups which are introduced with high stereo and regioselectivity, as well as processes for their synthesis.

Abstract: A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, or olanzapine.

Abstract: Low-hygroscopic anhydrous mirtazapine crystals having a hygroscopic degree of not more than 0.6% by weight when the crystals are stored in the air having a relative humidity of 75% at 25° C. under atmospheric pressure for 500 hours; a process for preparing anhydrous mirtazapine crystals having a hygroscopic degree of not more than 0.6% by weight when the crystals are stored in the air having a relative humidity of 75% at 25° C. under atmospheric pressure for 500 hours, comprising drying crystals of mirtazapine hydrate; a crystal of a mirtazapine hydrate represented by the formula (I): wherein n is an integer of 1 to 5; and a process for preparing crystals of a mirtazapine hydrate, comprising crystallizing a crude mirtazapine using a water-soluble organic solvent and water. The anhydrous mirtazapine crystals can be suitably used, for instance, as an antidepressant.

Abstract: The present invention includes compound of formula (I), or a derivative thereof, wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclcyl and the alkyl moieties may each inedepently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention inlcudes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

Abstract: Bis-sulfonamido hydroxyethylamino compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to retroviral protease inhibiting compounds of the formula: or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein the variables are as defined herein.

Abstract: Phenoxy amine compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: This invention discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile comprising combining an amine compound with a cyanoacetic acid and an acid catalyst to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline in an alcoholic solvent and a trialkylorthoformate to yield a 3-amino-2-cyanoacrylamide; combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride in acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 4-amino-3-quinolinecarbonitrile and also discloses a process for the preparation of a 7-amino-thieno[3,2-b]pyridine-6-carbonitrile comprising combining a disubstituted 3-amino thiophene with a cyanoacetamide and trialkylorthoformate in an alcoholic solvent to obtain a 3-amino-2-cyanoacrylamide; and combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride and acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 7-amino-

Abstract: Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or modulating ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

Abstract: The invention relates to novel ?1-pyrrolines of the formula (I) in which R1, R2, R3, R4, A1, A2, R5, R6, R7, R8, R9 and Q are as defined in the disclosure, to a process for preparing these compounds and to their use for controlling pests.

Abstract: A process for the preparation of the insecticide imidacloprid includes the reaction of 2-chloro-5-chloromethyl pyridine with 2-nitroiminoimidazolidine, carried out in the molar ratio of 1:1 to 1:1.2, in the presence of an alkali metal hydroxide in an aprotic solvent at 45 to 60° C. under stirring.

Abstract: The invention relates to the use of compounds of formula for the preparation of medicines designed for the treatment of neuronal and cerebral disorders. The invention also relates to the compounds of formula: a process for their preparation and the pharmaceutical compositions containing them.

Abstract: The present invention relates to a process for producing efficiently glutamic acid derivatives (including salts thereof) such as monatin by converting a substituted ?-keto acid of formula (1) into a glutamic acid derivative of formula (2) in the presence of an enzyme catalyzing conversion of the same

Abstract: The present invention relates to processes for the production of 2-oxa-3-one androstane derivatives. The processes comprise reacting a 3-one androstane derivative with ozone to form a 2-oxa-3-one androstane derivative.

Abstract: An epoxytriazole derivative (V) useful as an intermediate for anti-fungal agents and an intermediate therefor having high quality can be produced economically and efficiently by the following industrial means. A compound of the following formula (I) is reacted with trimethyloxosulfonium salt and the like in the presence of a base to give compound (II), this compound is converted to compound (IV), and this compound is reacted with 1,2,4-triazole in the presence of a base. wherein Ar is a phenyl group optionally substituted by 1 to 3 halogen atom(s) or trifluoromethyl group, R is a hydrogen atom or lower alkyl group, and X is a leaving group.

Abstract: A method for concentrating trans-lutein esters from marigold oleoresin, which includes blending the oleoresin with a solvent and a co-solvent of lower alkanols and recovering a precipitate enriched with trans-lutein esters at a temperature of above 22° C. The recovery of the trans-lutein esters is greater using the alkanol blend than when using only a lower alkanol in the said blend. The process is most useful using a lower-grade, commercially available oleoresin, thereby helping small producers, who do not have access to higher-grade oleoresin made through backward integration to marigold cultivation and harvest.

Abstract: The present invention relates to catalytic compositions for esterification, transestrification and polycondensation reactions, a process for the catalysis of said reactions employing such catalytic compositions and polyesters for resins obtainable by this process.

Abstract: A composition having the formula I where R1 and R2 are independently hydrogen, C1 to C12 linear and branched alkyl, C3 to C12 cycloalkyl, aryl, C1 to C12 alkoxy, F, Cl, SO3, C1 to C12 perfluoroalkyl, and N(CH3)2, R3 is independently selected from the group consisting of hydrogen, C1 to C12 linear and branched alkyl, C3 to C12 cycloalkyl, aryl, and 2,2,2-trifluoroethyl, A is —C(R4)—, —(CH2)x—, —(CH2)xNH(CH2)x—, or —CY2CY2—, where R4 is a hydrocarbyl, halosubstituted hydrocarbyl, or alkoxy group of from 1 to 12 carbon atoms, x is an integer from 1 to 12, and Y is halogen, and X is halogen, triflate, acetate, trifluoroacetate, hydride, or tetrafluoroborate. When combined with an activating co-catalyst is useful in polymerizing olefinic monomers.

Abstract: Alpha-olefin are manufactured in high yield and with very high selectivity by contacting ethylene with an iron complex of a selected 2,6-pyridinedicarboxaldehyde bisimine or a selected 2,6-diacylpyridine bisimine, and in some cases a selected activator compound such as an alkyl aluminum compound. Novel bisimines and their iron complexes are also disclosed. The ?-olefin are useful as monomers and chemical intermediates.

Abstract: The invention relates to intermediate compounds of the formula wherein R1 is H or a protecting group, R2 and R3 each independently represent H, methyl, or a leaving group, provided that at least one, but not both, of R2 and R3 is a leaving group. The intermediate compounds are useful for the synthesis of discodermolide, its derivatives, and related compounds.

Abstract: Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.

Abstract: The invention concerns a continuous method for preparing ethyl lactate by esterifying lactic acid with ethanol, in the presence of a catalyst which comprises reacting said lactic acid with ethanol in an initial ethanol/lactic acid mol ratio not less than 2.5, in the presence of a catalyst, at a reflux of the reaction medium of about 100° C. under absolute pressure ranging between 1.5 to 3 bars.

Abstract: The present invention includes optical coatings containing ultraviolet curable monomers employing a bromine substituted fluorene structure. The fluorene backbone of the monomers of the present invention may also be functionalized with one or more polymerizable or reactive functionalities, and most readily at the 9 position. Compositions of the present invention include the reactive bromosubstituted fluorenes combined with inorganic nanoparticles, particularly nanoparticles with reactive surface modifiers exhibiting polymerizable functionality. Reactive high index nanoparticles such as surface modified zirconia are contemplated.

Abstract: The invention provides alkene fluoroalkanol and fluorinated polyol precursors to fluoroalkanol-substituted ?,?-unsaturated esters. The fluoroalkanol-substituted ?,?-unsaturated esters are olefins that can be readily polymerized to provide fluoroalkanol-substituted polymers useful in lithographic photoresist compositions. Also provided are methods for synthesizing the alkene fluoroalkanol and fluorinated polyol precursors.

Abstract: An unsaturated, cyclic orthoester is prepared by reacting an unsaturated carboxylic acid with glycidol, thereby obtaining a reaction mixture; and adding an orthoester to the reaction mixture, thereby obtaining said unsaturated, cyclic orthoester.

Abstract: Methods of removing alkyl alkanesulfonate esters from aqueous or anhydrous compositions are provided. The invention provides methods for the conversion of alkyl alkanesulfonate esters of the formula RSO3R? to the corresponding acids of the formula RSO3H. The alkyl alkanesulfonate esters are present in an organic medium, which may contain significant amounts of water or which may be anhydrous or substantially anhydrous. In some embodiments, the invention provides methods for purifying aqueous or anhydrous alkanesulfonic acids by removing alkyl alkanesulfonate esters.

Abstract: A multitube reactor, wherein tubes having smaller tolerance between a nominal size and actual sizes are used as reaction tubes to stably perform a high yield reaction for a long period, a catalyst is filled into the reaction tubes so that the catalyst layer peak temperature portions of the reaction tubes are not overlapped with the connection sites thereof with baffles to effectively prevent hot spots from occurring and stably perform a reaction for a long period without the clogging of the reaction tubes, a heat medium and raw material gas are allowed to flow in the direction of a countercurrent and a specified type of catalyst is filled into the reaction tubes so that activity is increased from the inlet of the raw material gas to the outlet thereof to prevent the autooxidation of products so as to prevent equipment from being damaged due to the reaction, and, at the time of starting, gas with a temperature of 100 to 400° C.

Abstract: It is an object of the present invention to solve difficulty in production and to provide a process to obtain fluorinated sulfonyl fluoride compound having various molecular structures efficiently at a low cost. That is, the present invention provides a process which comprises reacting (FSO2—)nRA(-E-RB)m (1F) with fluorine in a liquid phase to form (FSO2—)nRAF(-EF-RBF)m (2), and decomposing this compound to obtain (FSO2—)nRAF(-EF1)m (3), provided that RA is a (n+m) valent organic group having at least two carbon atoms, RAF is a group having RA fluorinated, or the like, each of RB and RBF is a fluorinated monovalent organic group, or the like, E is —COOCH2— or the like, EF is —COOCF2— or the like, EF1 is —COF or the like, n is an integer of at least 2, and m is an integer of at least 1.

Abstract: Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.

Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

Abstract: The present invention relates to open chain alkoxyamine compounds, a polymerizable composition comprising a) at least one ethylenically unsaturated monomer and b) at least one open chain alkoxyamine compound. Further aspects of the present invention are a process for polymerizing ethylenically unsaturated monomers, and the use of open chain alkoxyamine compounds for controlled polymerization. The intermediate N-oxyl derivatives, a composition of the N-oxyl derivatives with ethylenically unsaturated monomers and a free radical initiator X, as well as a process and their use for polymerization are also subjects of the present invention.

Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Abstract: A fluorine compound represented by Formula (1) is provided. The above fluorine compound is effective for introducing a fluorine atom into a compound having an active group such as an oxygen-containing functional group, and it can be used for uses of surface treatment, cleaning and coating. Further, after the fluorination reaction, the above compound is recovered and can be reused as a starting material for producing the above fluorine compound, and it is useful for various fluorination processes. (wherein X represents a nitrogen or phosphorus atom; R0, R1, and R2 represent hydrogen, an alkyl group or aryl group which may have a substituent, and they each may be the same or different; and R0, R1, and R2 may be combined with each other to form a ring).

Abstract: The present invention relates to novel brominated phenoxy compounds and to process for their preparation. More particularly, the present invention relates to synthesis of novel dibromodiphenyl ether starting from Cashew Nut Shell Liquid (CNSL);—a renewable resource material. The present invention particularly relates to novel 1-bromo-4-(4?-bromophenoxy)-2-pentadecylbenzene and to a method for it's preparation.

Abstract: The invention relates to the use of polymers which contain between 1 and 99 mol-% structural units of formula 1, wherein R1 represents hydrogen or C1-C6 alkyl, R2 represents C1-C24-alkyl, C2-C24-alkylene or a C6-C18-aryl radical, which can be substituted with a C1-C12-alkyl group, A represents identical or different C2-C4 alkylene radicals and, x, represents whole number from 2-40 in quantities from 0.01-2 wt-%, in quantities from 0.01 to 2 wt-%, in relation to the aqueous phase. The polymers can be used as gas hydrate inhibitors.

Abstract: Improved Ni catalysts for hydrogenation reactions are disclosed. The catalysts are useful for hydrogenation such as selective hydrogenation of acetylenic impurities in crude olefin and diolefin streams. The catalysts are prepared by depositing nickel on a porous support which has the following specific physical properties; BET surface area of from 30 to about 100 m2/g, total nitrogen pore volume of from 0.4 to about 0.9 cc/g, and an average pore diameter of from about 110 to 450 ? with or without modifiers of one or more elements selected from the group consisting of Cu, Re, Pd, Zn, Mg, Mo, Ca and Bi.

Abstract: A catalyst for producing a liquefied petroleum gas according to the present invention comprises a Pd-based methanol synthesis catalyst component and a ?-zeolite catalyst component. It can be used in a reaction of carbon monoxide and hydrogen to give a hydrocarbon containing propane or butane as a main component, i.e., a liquefied petroleum gas, with high activity, high selectivity and high yield. Furthermore, the catalyst has a longer catalyst life with less deterioration.

Abstract: A process is described for producing phenylalkanes by alkylating at least one aromatic compound using at least one linear olefin containing 9 to 16 carbon atoms per molecule. The alkylation reaction is carried out in the presence of at least two different catalysts used in at least two distinct reaction zones. The selectivity for a monoalkylated products of the catalyst contained in the first reaction zone is lower than that for the catalyst contained in the second reaction zone located downstream of the first in the direction movement of the fluids.

Abstract: Disclosed is an alkylation reactor for preparing ethylbenzene. The reactor comprises a monolith catalyst system that includes a monolith support impregnated or co-formed with a catalyst suitable to catalyze the alkylation of benzene with ethylene. The catalyst may be selected from, for example, zeolites such as beta zeolite and MCM-22 zeolite, and fixed super acids. Also disclosed is a method of preparing ethylbenzene by alkylating a mixture of benzene and ethylene in an alkylation reactor comprising a monolith catalyst system, including a monolith support impregnated or co-formed with a suitable catalyst. In one embodiment the invention provides a convenient means of upgrading an existing reactor that has previously been used for conventional liquid phase alkylations such as those catalyzed by aluminum trichloride. The inventive alkylation method may be effectively and advantageously carried out under critical or near critical conditions, if desired.

Abstract: An alkylating process for the production of at least one of 2-, 3-, 4-, 5-, and 6-phenylalkanes by alkylation of an aromatic compound with a feedstock containing at least one olefin comprising at least 9 carbon atoms per molecule, in the presence of a catalyst comprising at least one substrate based on at least a zeolite and a non-zeolitic silica-alumina matrix with a low content of macropores, whereby said matrix contains an amount of more than 5% by weight and less than or equal to 95% by weight of silica (SiO2), whereby said process is carried out at a temperature of between 30 and 400° C., a pressure of between 0.1 and 10 MPa, an hourly volumetric flow rate of 0.50 to 200 h?1, and an aromatic compound/olefin molar ratio of between 1:1 and 50:1.